These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23346997)

  • 21. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
    Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
    World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance.
    Degertekin B; Hussain M; Tan J; Oberhelman K; Lok AS
    J Hepatol; 2009 Jan; 50(1):42-8. PubMed ID: 19019484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
    van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
    Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
    Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
    J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
    Nakanishi H; Kurosaki M; Asahina Y; Onuki Y; Ueda K; Nishimura Y; Tsuchiya K; Kitamura T; Uchihara M; Miyake S; Enomoto N; Izumi N
    Intervirology; 2005; 48(6):381-8. PubMed ID: 16024942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
    Roque-Afonso AM; Férey MP; Mackiewicz V; Fki L; Dussaix E
    Antivir Ther; 2003 Dec; 8(6):627-34. PubMed ID: 14760897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
    Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX
    Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
    Karatayli E; Idilman R; Karatayli SC; Cevik E; Yakut M; Seven G; Kabaçam G; Bozdayi AM; Yurdaydin C
    Antivir Ther; 2013; 18(1):77-85. PubMed ID: 22878399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
    Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
    J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
    Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.